U.S. Markets closed

Soligenix, Inc. (SNGX)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.32-0.03 (-1.28%)
At close: 4:00PM EDT
People also watch
CBLIAPHBIDXGFCSCHTGM
Interactive chart
Previous Close2.35
Open2.28
Bid2.26 x 400
Ask4.19 x 300
Day's Range2.28 - 2.38
52 Week Range1.90 - 8.90
Volume40,361
Avg. Volume634,358
Market Cap13.16M
Beta0.11
PE Ratio (TTM)-2.04
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Zacks Small Cap Research17 days ago

    SNGX: SGX942: Cancer Control is an “Added Bonus” for OM Treatment

    Based on three platform technologies, SNGX has built a diversified pipeline targeting multiple indications. The Company’s oral BDP is in various development stages for a variety of indications, most notably, in pediatric Crohn’s disease, where they will be initiating a Phase III study soon for SGX203.

  • Soligenix, Inc. :SNGX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 29, 2017
    Capital Cube2 months ago

    Soligenix, Inc. :SNGX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 29, 2017

    Categories: Yahoo Finance Get free summary analysis Soligenix, Inc. reports financial results for the quarter ended December 31, 2016. We analyze the earnings along side the following peers of Soligenix, Inc. – PharmAthene, Inc., Emergent BioSolutions Inc., Cleveland BioLabs, Inc., Sanofi Sponsored ADR, Onconova Therapeutics Inc., Pfizer Inc., Teva Pharmaceutical Industries Limited Sponsored ADR and Athersys, Inc. (PIP-US, ... Read more (Read more...)

  • Zacks Small Cap Research2 months ago

    Soligenix (SNGX): A Key Player in the Biodefense Space

    On March 10, 2017, Soligenix (SNGX) announced that it will present results from its ricin toxin vaccine (RiVax™) development program on March 15 at the Society of Toxicology 56th Annual Meeting. The poster is titled: Verification of Lethal Doses of Inhaled Ricin in Rhesus Macaques to Support Vaccine Development. RiVax™ is the Company's proprietary vaccine candidate for the prevention of exposure to ricin toxin that utilizes a unique antigen that is completely devoid of the toxic activity of ricin.